Sunday, September 13, 2026

Less Than Two Hours Before The Market Open, Illumina Is Down By 5%

ViaNews Editorial Team

January 16, 2024

Less Than Two Hours Before The Market Open, Illumina Is Down By 5%

(VIANEWS) - The NASDAQ opens in less than two hours and Illumina's pre-market value is already 5.49% down.

Illumina's last close was $138.04, 42.13% under its 52-week high of $238.55.

The last session, NASDAQ ended with Illumina (ILMN) sliding 2.11% to $138.04. NASDAQ jumped 0.02% to $14,972.76, following the last session's upward trend on what was a somewhat positive trend exchanging session.

About Illumina

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Earnings Per Share

As for profitability, Illumina has a trailing twelve months EPS of $-7.1.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -17.82%.

Sales Growth

Illumina's sales growth is negative 1% for the current quarter and negative 3.4% for the next.

Yearly Top and Bottom Value

Illumina's stock is valued at $138.04 at 08:24 EST, way below its 52-week high of $238.55 and way higher than its 52-week low of $89.00.

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.4%, now sitting on 4.46B for the twelve trailing months.

Volume

Today's last reported volume for Illumina is 1564798 which is 42.29% below its average volume of 2711710.

More news about Illumina (ILMN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Chip Boom Lifts Semiconductors as Export-Control Gaps Persist
AI infrastructure demand is fueling a broad semiconductor rally — Broadcom's AI chip revenue and Q4 guidance, Amazon's custom silicon crossing a $25B annual run rate, and bullish analyst calls on Micron and Sandisk tied to a memory chip boom underestimated even by bulls — with ASML rallying on sympathy. That momentum runs alongside unresolved US-China tech tensions: Belgium's arrest of a suspect for stealing chip technology for China and a blacklisted Chinese firm still acquiring Nvidia's top AI chips show export-control enforcement lagging the pace of AI chip demand.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com
Less Than Two Hours Before The Market Open, Illumina Is Down By 5% | Via News